ERAMET (ER7.DE) Fundamental Analysis & Valuation

FRA:ER7 • FR0000131757

Current stock price

47.28 EUR
-1.88 (-3.82%)
Last:

This ER7.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ER7.DE Profitability Analysis

1.1 Basic Checks

  • ER7 had negative earnings in the past year.
  • In the past year ER7 has reported a negative cash flow from operations.
  • Of the past 5 years ER7 4 years were profitable.
  • Of the past 5 years ER7 4 years had a positive operating cash flow.
ER7.DE Yearly Net Income VS EBIT VS OCF VS FCFER7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • With a Return On Assets value of -1.58%, ER7 is not doing good in the industry: 70.45% of the companies in the same industry are doing better.
  • The Return On Equity of ER7 (-9.29%) is worse than 77.27% of its industry peers.
  • ER7 has a Return On Invested Capital of 0.80%. This is in the lower half of the industry: ER7 underperforms 70.45% of its industry peers.
  • ER7 had an Average Return On Invested Capital over the past 3 years of 7.29%. This is in line with the industry average of 8.65%.
  • The 3 year average ROIC (7.29%) for ER7 is well above the current ROIC(0.80%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROIC 0.8%
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ER7.DE Yearly ROA, ROE, ROICER7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

  • In the last couple of years the Profit Margin of ER7 has declined.
  • ER7 has a Operating Margin of 1.91%. This is in the lower half of the industry: ER7 underperforms 68.18% of its industry peers.
  • In the last couple of years the Operating Margin of ER7 has declined.
  • ER7's Gross Margin of 68.15% is amongst the best of the industry. ER7 outperforms 88.64% of its industry peers.
  • In the last couple of years the Gross Margin of ER7 has grown nicely.
Industry RankSector Rank
OM 1.91%
PM (TTM) N/A
GM 68.15%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
ER7.DE Yearly Profit, Operating, Gross MarginsER7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ER7.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ER7 is destroying value.
  • Compared to 1 year ago, ER7 has more shares outstanding
  • ER7 has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ER7 has an improved debt to assets ratio.
ER7.DE Yearly Shares OutstandingER7.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ER7.DE Yearly Total Debt VS Total AssetsER7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • Based on the Altman-Z score of 1.06, we must say that ER7 is in the distress zone and has some risk of bankruptcy.
  • ER7's Altman-Z score of 1.06 is on the low side compared to the rest of the industry. ER7 is outperformed by 77.27% of its industry peers.
  • A Debt/Equity ratio of 2.03 is on the high side and indicates that ER7 has dependencies on debt financing.
  • ER7's Debt to Equity ratio of 2.03 is on the low side compared to the rest of the industry. ER7 is outperformed by 88.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Altman-Z 1.06
ROIC/WACC0.09
WACC9.08%
ER7.DE Yearly LT Debt VS Equity VS FCFER7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • ER7 has a Current Ratio of 1.54. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of ER7 (1.54) is worse than 65.91% of its industry peers.
  • ER7 has a Quick Ratio of 1.06. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
  • ER7 has a Quick ratio (1.06) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.06
ER7.DE Yearly Current Assets VS Current LiabilitesER7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ER7.DE Growth Analysis

3.1 Past

  • ER7 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -219.63%.
  • The earnings per share for ER7 have been decreasing by -64.00% on average. This is quite bad
  • The Revenue has decreased by -6.91% in the past year.
  • Measured over the past years, ER7 shows a decrease in Revenue. The Revenue has been decreasing by -4.39% on average per year.
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%

3.2 Future

  • The Earnings Per Share is expected to decrease by -55.03% on average over the next years. This is quite bad
  • Based on estimates for the next years, ER7 will show a small growth in Revenue. The Revenue will grow by 6.17% on average per year.
EPS Next Y-333.81%
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%
EPS Next 5Y-55.03%
Revenue Next Year4.29%
Revenue Next 2Y6.01%
Revenue Next 3Y6.87%
Revenue Next 5Y6.17%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ER7.DE Yearly Revenue VS EstimatesER7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B 5B
ER7.DE Yearly EPS VS EstimatesER7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. ER7.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • ER7 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 51.92 indicates a quite expensive valuation of ER7.
  • Based on the Price/Forward Earnings ratio, ER7 is valued a bit more expensive than the industry average as 72.73% of the companies are valued more cheaply.
  • ER7 is valuated expensively when we compare the Price/Forward Earnings ratio to 23.28, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 51.92
ER7.DE Price Earnings VS Forward Price EarningsER7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as ER7.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.96
ER7.DE Per share dataER7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80 100

4.3 Compensation for Growth

  • A cheap valuation may be justified as ER7's earnings are expected to decrease with -6.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ER7.DE Dividend Analysis

5.1 Amount

  • No dividends for ER7!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ER7.DE Fundamentals: All Metrics, Ratios and Statistics

ERAMET

FRA:ER7 (3/20/2026, 7:00:00 PM)

47.28

-1.88 (-3.82%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)02-18
Earnings (Next)04-23
Inst Owners14.01%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.36B
Revenue(TTM)2.88B
Net Income(TTM)-97.00M
Analysts80
Price Target61.41 (29.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP-44.33%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.57%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-28%
EPS NY rev (3m)-2269.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)5.29%
Revenue NY rev (3m)1.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 51.92
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 2.52
EV/EBITDA 13.96
EPS(TTM)-3.42
EYN/A
EPS(NY)0.91
Fwd EY1.93%
FCF(TTM)-25.76
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS100.31
BVpS36.3
TBVpS18.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROCE 1.16%
ROIC 0.8%
ROICexc 0.95%
ROICexgc 1.09%
OM 1.91%
PM (TTM) N/A
GM 68.15%
FCFM N/A
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexgc growth 3Y-56.22%
ROICexgc growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Debt/EBITDA 10.29
Cap/Depr 403.31%
Cap/Sales 21.11%
Interest Coverage 0.34
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.06
Altman-Z 1.06
F-Score2
WACC9.08%
ROIC/WACC0.09
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-333.81%
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%
EPS Next 5Y-55.03%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
Revenue Next Year4.29%
Revenue Next 2Y6.01%
Revenue Next 3Y6.87%
Revenue Next 5Y6.17%
EBIT growth 1Y-51.75%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year-4.34%
EBIT Next 3Y30.08%
EBIT Next 5Y23.12%
FCF growth 1Y-850%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.46%
OCF growth 3YN/A
OCF growth 5YN/A

ERAMET / ER7.DE Fundamental Analysis FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.


Can you provide the valuation status for ERAMET?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.


What is the profitability of ER7 stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.


Can you provide the financial health for ER7 stock?

The financial health rating of ERAMET (ER7.DE) is 2 / 10.


How sustainable is the dividend of ERAMET (ER7.DE) stock?

The dividend rating of ERAMET (ER7.DE) is 0 / 10 and the dividend payout ratio is -44.33%.